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Introduction {#prp2302-sec-0001}
============

Currently recommended combination antimalarial therapy for treatment of falciparum malaria, is artemisinin‐based combination therapies (ACTs). Artesunate + amodiaquine (AS + AQ) and artemether‐lumefantrine (AL), have been adopted by many countries in sub‐Saharan Africa, and Nigeria. These combinations therapy is still highly effective going by reports from clinical trials (FMoH Abuja [2011](#prp2302-bib-0015){ref-type="ref"}; Greenwood et al. [2005](#prp2302-bib-0018){ref-type="ref"}). However, the safety and tolerability of these drug combinations still pose some concern to healthcare providers and may be source of treatment interruption among the populations (Simooya et.al 2005), more so in the presence of comorbidities and use of other medicines these concern might be heightened. Recent reviews of studies of the safety of these new combination regimens has shown safety reassurance, identifying no serious concerns, but to date evaluations of drug safety and tolerability have been limited (Simooya et. al. 2005; Bassi et al. [2012](#prp2302-bib-0002){ref-type="ref"}; Fanello et al. [2006](#prp2302-bib-0011){ref-type="ref"}; Karema et al. [2006](#prp2302-bib-0023){ref-type="ref"}; Bukirwa et al. [2006](#prp2302-bib-0004){ref-type="ref"}; Kamya et al. [2007](#prp2302-bib-0022){ref-type="ref"}). Most of the ACTs safety data have been from clinical trials treatment evaluating single episodes of malaria in the absence of comorbidities.

Taking several medicines, whether prescription or over‐the‐counter, contributes to the risk of having an ADR. The number and severity of ADRs increases disproportionately as the number of drugs taken increases. "Many definitions are applied for polypharmacy. It is different from scholar to scholar but the basic concept of taking more medications at the same time than are clinically appropriate remains constant" (Rambhade et al. [2012](#prp2302-bib-0035){ref-type="ref"}). It implies to the prescription of too many medications for a particular patient, with a possibility of increased risk of ADRs. The more the number of medications that are prescribed the greater the possibility of polypharmacy, but this does not necessarily mean however that patients should not take many medications (Bushardt et al. [2008](#prp2302-bib-0005){ref-type="ref"}).

Drugs that are useful in the management of one disease may precipitate or worsen another, e.g., some beta‐blockers taken for heart disease or high blood pressure can worsen asthma and make it hard for people with diabetes to tell when their blood sugar is too low (Kurnik et al. [2004](#prp2302-bib-0025){ref-type="ref"}). In addition prednisone which is used for treating several conditions can aggravate congestive heart failure and cause fluid retention. Some of these interactions may have an insidious onset, and as a result careful and close medical attention is mandatory (Boer et al.[2003](#prp2302-bib-0003){ref-type="ref"}). Concomitant patient\'s disease may also influence susceptibility to ADRs (Rambhade et al. [2012](#prp2302-bib-0035){ref-type="ref"}). For example, increase in the frequency of idiosyncratic toxicity with anti‐infective drugs such as trimethomprim‐sulphamethoxazole (Hanses et al. [2009](#prp2302-bib-0019){ref-type="ref"}). The presence of multiple disease conditions predispose patients to ADRs due to the combination of the presence of many diseases and the use of many medicines (Muaed [2012](#prp2302-bib-0031){ref-type="ref"}). AIDS for instance predisposes to ADRs, such that the incidence of Stevens--Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) have been reported to be higher among those particular patients. A study showed that one of the most commonly used medications among patients who developed TEN and SJS is trimethoprim/sulfamethoxazole (Boer et al. [2003](#prp2302-bib-0003){ref-type="ref"}; Mittman et al. [2012](#prp2302-bib-0030){ref-type="ref"}; Muaed [2012](#prp2302-bib-0031){ref-type="ref"}). "A recent study of a multivariate logistic regression indicated that a T CD4 + count of lower than 200 cells/mm3 increased the risk of hepatotoxicity by a factor of 1.233(*P* \< 0.001) and that coinfection with hepatitis B or C viruses increased this risk by a factor of 18.187" (*P* = 0.029) (Lima and Melo [2012](#prp2302-bib-0026){ref-type="ref"}). There is a paucity of publications on ADRs in patients with malaria and other comorbidities treated with ACTs. Therefore, this study seeks to assess the impact comorbidity on the ADR profile of in malaria patients taking ACTs. Specifically, the objectives of the study were to evaluate the incidence of adverse drug events among the cohort of patients with and without comorbidities, estimate the risk of developing adverse events among patients with and without comorbidities, identify the types and frequency of adverse drug reaction (or AEs) in patients with and without comorbidity and determine comorbidities that are associated with development of AEs.

Subjects and Methods {#prp2302-sec-0002}
====================

The study was part of a larger observational, prospective cohort event monitoring program of adverse events in a cohort of patients treated with either Artemeter‐Lumefantrine (AL) or Artesunate Amodiaquine (AA), carried out in 18 health care facilities spread across the six geopolitical zones of Nigeria between 31st and May 2012.

From the database of the over 10,000 patients in the CEM study, we identified 1000 patients with comorbidity (all patients in the database with comorbidities) and extracted their demographic and clinical data from the database and compared with a group of 1000 patients from the same database systematically (every 10th patients ID was pick until we selected 1000 and if the 10 is with comorbidity, the next number is picked) selected patients who received ACTs but had no comorbidity.

All age groups and both sexes with the diagnosis of malaria with or without co‐morbidity on treatment with ACT and other drugs were included in the study group. The selected patients were categorized into group "A" those with comorbidity and group "B" those without comorbidity while study medications were assessed for adverse events beginning with the day 0 (first treatment day) of malaria.

An adverse event was defined as any untoward medical occurrence, irrespective of its suspected relationship to the study medications as per International Conference of Harmonization (ICH) guidelines (ICH‐E6 [1996](#prp2302-bib-0021){ref-type="ref"}). A serious adverse event was defined as any adverse experience that resulted in death, life‐threatening experience, participant hospitalization, persistent or significant disability or incapacity, or specific medical or surgical intervention to prevent serious outcome.

Data of 2000 patients was analysed with for statistical analyses using SPSS VER 21. (IBM--SPSS [2011](#prp2302-bib-0020){ref-type="ref"}). Result was then presented as frequency distribution, percentages, and Chi Square to study relationships. Results were also presented in tables. Potential risk factors such as age, drug regimen, gender, pregnancy, and use of traditional medications to statistical were subjected to analysis using multinomial logistic regressions.

Results {#prp2302-sec-0003}
=======

Socio‐demographic characteristics {#prp2302-sec-0004}
---------------------------------

A total of 1979 patient suspected adverse events to ACT with or without comorbidity were reported. There were 979 patients with comorbid conditions, mean age 38.3 ± 17.5 years and 1000 patients without comorbidity 23.8 ± 17.2 years (range 3 months‐89 years), *P* \< 0.001, with M/F sex ratio of 1.13 *P* \< 0.001 that was studied (Table [1](#prp2302-tbl-0001){ref-type="table-wrap"}). The mean weight of the patients was 64.6 ± 22.7 kg and 50.1 ± 27.0 kg, *P* \< 0.001 among those with comorbidity and without comorbidity, respectively (Table [2](#prp2302-tbl-0002){ref-type="table-wrap"}). 45.9% (913) patients received AA while 54.1% (1075) received AL among the cohort.

###### 

Demographic characteristics

  Age (year)   Comorbidity (*n* = 979)   No comorbidity (*n* = 999)   *χ* ^2^   *P*‐value
  ------------ ------------------------- ---------------------------- --------- -----------------------------------------------
  \<4          55 (5.6)                  188 (18.8)                   79.960    \<0.001[a](#prp2302-note-0009){ref-type="fn"}
  4--8.9       44 (4.5)                  103 (10.3)                   24.311    \<0.001[a](#prp2302-note-0009){ref-type="fn"}
  9--14.9      27 (2.8)                  70 (7.0)                     19.143    \<0.001[a](#prp2302-note-0009){ref-type="fn"}
  ≥15          853 (87.1)                638 (63.9)                   144.214   \<0.001[a](#prp2302-note-0009){ref-type="fn"}
  Mean age     38.3 ± 17.5               23.8 ± 17.2                            
  Median age   40                        25                                     
  Sex                                                                           
  Male         279 (28.5)                445 (44.5)                   54.863    \<0.001[a](#prp2302-note-0009){ref-type="fn"}
  Female       700 (71.5)                554 (55.5)                             

Student\'s *t* = 18.465; *P* \< 0.001.

Mean difference = 14.4 (95% CI of difference = 12.9--16.0).

Statistically significant *df* = 1.
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Symptoms and signs of Malaria {#prp2302-sec-0005}
-----------------------------

A total of 9189 signs and symptoms of suggestive of malaria were reported among 1988 patients, making an average 4--5 symptoms (Table [2](#prp2302-tbl-0002){ref-type="table-wrap"}) of malaria per patient at presentation. The most common symptoms were fever 1052 (11.5%), headache 1046(11.4%), weakness 958 (10.4%), joint pains 905(9.9%), tiredness 888 (9.2%), body pains 844 (9.2%), etc as seen in Table [3](#prp2302-tbl-0003){ref-type="table-wrap"}. All signs and symptoms were mild to moderate.

###### 

Anthropometrics

  Variable      Mean ± Standard deviation   Student\'s *t* statistic   *P*‐value   Mean diff                                       95% CI of diff          
  ------------- --------------------------- -------------------------- ----------- ----------------------------------------------- ---------------- ------ ------
  Weight (kg)   64.6 ± 22.7                 50.1 ± 27.0                12.773      \<0.001[a](#prp2302-note-0109){ref-type="fn"}   14.5             12.3   16.8
  Height (cm)   155.3 ± 23.9                154.5 ± 25.4               0.588       0.555                                           0.7              −1.7   3.1

Statistically significant.
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###### 

Symptoms of malaria

  Variable          Comorbidity (*n* = 979)   No Comorbidity (*n* = 999)   *χ* ^2^   *P* ‐value             
  ----------------- ------------------------- ---------------------------- --------- ------------ --------- -----------------------------------------------
  Fever             590                       60.3                         462       46.2         39.030    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Headache          645                       66.0                         401       40.1         131.510   \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Joint pain s      516                       52.7                         389       38.9         37.763    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Abdominal pains   227                       23.2                         197       19.7         3.530     0.060
  Vomiting          93                        9.5                          180       18.0         30.159    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Diarrhea          54                        5.5                          83        8.3          5.981     0.014[a](#prp2302-note-0119){ref-type="fn"}
  Nausea            166                       17.0                         148       14.8         1.698     0.193
  Tiredness         390                       39.8                         498       49.8         20.040    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Weakness          513                       52.4                         445       44.5         12.218    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Dizziness         175                       17.9                         60        6.0          66.537    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Body pains        526                       53.7                         318       31.8         96.910    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Chills & Rigors   192                       16.6                         120       12.0         21.496    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Bitter taste      380                       38.8                         116       11.6         194.758   \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Cough             252                       25.7                         277       27.7         0.997     0.318
  Poor appetite     305                       31.2                         201       20.1         31.622    \<0.001[a](#prp2302-note-0119){ref-type="fn"}
  Temperature       145                       14.8                         120       12.0         3.339     0.068

Statistically significant *df* = 1
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Out of the 979 patients with comorbidity, 352 (36%) were hypertensive, 22 (2.2) were hypertensive‐diabetes, others were peptic ulcer disease 161 (16.4%), HIV/AIDS 102 (10.4%), Diabetes 43 (4.4%), Asthma 42 (4.3%), osteoarthritis 30 (3.1%), and sickle cell disease 29 (3.0%). Although pregnancy is a physiologic condition, it was classified under comorbid conditions because of the special considerations with the use of artemisinin combination therapy Table [4](#prp2302-tbl-0004){ref-type="table-wrap"}.

###### 

Types and frequency of ADRs recorded

  ADR                        Patients with comorbidity *N* = 731 (%)   Patients without comorbidity *N* = 374(%)   Total *N* = 1105(%)
  -------------------------- ----------------------------------------- ------------------------------------------- ---------------------
  CNS                                                                                                              
  Dizziness                  86 (11.8)                                 67 (19.9)                                   153 (13.9)
  Headaches                  54 (7.3)                                  35 (9.4)                                    89 (8.1)
  Insomnia                   21 (2.9)                                  1 (0.3)                                     22 (2.0)
  Drowsiness                 14 (1.9)                                  3 (0.8)                                     17 (1.5)
  Restlessness               5 (0.7)                                   7 (1.9)                                     12 (1.1)
  Tiredness                  6 (0.8)                                   4 (1.1)                                     10 (0.9)
  Excessive sweating         7 (1.0)                                   1 (0.3)                                     8 (0.7)
  Palpitations               3 (0.4)                                   4 (1.1)                                     7 (0.6)
  Somnolence                 3 (0.4)                                   3 (0.8)                                     6 (0.5)
  Tremor                     5 (0.7)                                   0 (0.0)                                     5 (0.5)
  Blurred visions            3 (0.4)                                   1 (0.3)                                     4 (0.4)
  Internal heat              0 (0.0)                                   3 (0.8)                                     3 (0.3)
  Migraine                   2 (0.3                                    0 (0.0)                                     2 (0.2)
  Paraesthesiae              1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Tinnitus                   1 (0.3)                                   0 (0.0)                                     1 (0.1)
  Musculoskeletal                                                                                                  
  Weakness                   263 (36.0)                                101 (27.0)                                  364 (32.9)
  Low Back Pain              11 (1.5)                                  11 (2.9)                                    22 (2.0)
  Back pain                  9 (1.2)                                   7 (1.9)                                     16 (1.4)
  Joint pains.               4 (0.6)                                   10 (2.7)                                    14 (1.3)
  Fatigue                    5 (0.7)                                   6 (1.6)                                     11 (1.0)
  Myalgia                    1 (0.1)                                   3 (0.8)                                     4 (0.4)
  Jaw swellings              2 (0.3)                                   0 (0.0)                                     2 (0.2)
  Neck swelling              1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Malaise                    0 (0.0)                                   1 (0.3)                                     1 (0.1)
  Gastrointestinal                                                                                                 
  Vomiting                   29 (4.0)                                  30 (8.0)                                    59 (5.3)
  Nausea                     36 (4.9)                                  14 (3.7)                                    50 (4.5)
  Abdominal pain             13 (1.8)                                  16 (4.3)                                    29 (2.6)
  Diarrhea                   21 (2.9)                                  8 (2.1)                                     29 (2.6)
  Increased appetite         13 (1.8)                                  6 (1.6)                                     19 (1.7)
  Abdominal discomfort       5 (0.7)                                   5 (1.3)                                     10 (0.9)
  Bitter taste               7 (1.0)                                   2 (0.5)                                     9 (0.8)
  Loss of appetite           8 (1.1)                                   1 (0.3)                                     9 (0.8)
  Anorexia                   5 (0.7)                                   2 (0.5)                                     7 (0.7)
  Epigastric pain            3 (0.4)                                   2 (0.5)                                     5 (0.5)
  Abdominal cramps           0 (0.0)                                   2 (0.5)                                     2 (0.2)
  Constipations              2 (0.3)                                   0 (0.0)                                     2 (0.2)
  Cardiovascular                                                                                                   
  Fainting Attack/collapse   3 (0.4)                                   1 (0.3)                                     4 (0.4)
  Hypertension               1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Pedal swelling             1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Hot Flushes                1 (1.1)                                   0 (0.0)                                     1 (0.1)
  Respiratory                                                                                                      
  URTI                       17 (2.3)                                  4 (1.1)                                     21 (2.0)
  Cough                      4 (0.6)                                   1 (0.3)                                     5 (0.5)
  Chest pains                3 (0.4)                                   1 (0.3)                                     4 (0.4)
  Difficulty in breathing    2 (0.3)                                   0 (0.0)                                     2 (0.2)
  Heaviness in chest         0 (0.0)                                   1 (0.3)                                     1 (0.1)
  Renal                                                                                                            
  Hematuria                  3 (0.4)                                   0 (0.0)                                     3 (0.3)
  Yellowish urine            3 (0.4)                                   0 (0.0)                                     3 (0.3)
  Increased frequency        2 (0.3)                                   0 (0.0)                                     2 (0.2)
  Facial swelling            1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Dermatological                                                                                                   
  Itching                    8 (1.1)                                   1 (0.3)                                     9 (0.9)
  Rashes                     0 (0.0)                                   3 (0.8)                                     3 (0.3)
  General                                                                                                          
  Fever                      25 (3.4)                                  7 (1.9)                                     32 (3.0)
  Chills & rigors            3 (0.4)                                   1 (0.3)                                     4 (0.4)
  Metabolic                                                                                                        
  Excessive thirst           3 (0.4)                                   0 (0.0)                                     2 (0.2)
  Jaw swellings              2 (0.3)                                   0 (0.0)                                     2 (0.2)
  Hypoglycemia               1 (0.1)                                   0 (0.0)                                     1 (0.1)
  Neck swelling              1 (0.1)                                   0 (0.0)                                     1 (0.1)
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Types and frequency of suspected adverse drug reactions {#prp2302-sec-0006}
-------------------------------------------------------

Table [4](#prp2302-tbl-0004){ref-type="table-wrap"} presents the types and frequency of ADRs recorded. There were 1105 suspected adverse drug reactions in all, of which 731 (66.2%) were recorded in patients with comorbidity, and 374 (34%) were in patients without comorbidity. The most predominant symptoms are weakness 364, dizziness 153, headache 89, vomiting 59, nausea 50, fever 32, abdominal pain 29, and insomnia 22. There were 1105 suspected adverse drug reactions in all, of which 731 (66.2%) were recorded in patients with comorbidity, and 374 (34%) were in patients without comorbidity. The most predominant events seen among those with comorbidity includes weakness 263(36%), dizziness 86 (11.8%), headache 54 (7.3), nausea 36 (4.9%), vomiting 29 (4.0%) and insomnia 21 (2.9%). However, in those with comorbidity, the most predominant events seen includes body weakness 101 (27%), dizziness 67 (19.1%), headache 35 (9.4%), vomiting 30 (8.8%), abdominal pain 16 (4.3%), and nausea 14 (3.4%). This gives prevalence of 19.6% among patients with co‐morbidity, while that of patients without co‐morbidity was 7.6%. Patients with co‐morbidity were three times more likely to have adverse drug reaction than those without co‐morbidity and it could be as low as two times and as high as four times (Odds ration = 2.96; 95% CI = 2.23--3.93) Table [5](#prp2302-tbl-0005){ref-type="table-wrap"}.

###### 

Occurrence of adverse drug reaction (ADR)

  Co‐morbidity                                                                     Adverse drug reaction   Odds ratio   95% CI                                                       
  -------------------------------------------------------------------------------- ----------------------- ------------ -------- -------------------------------------------- ------ ------
  Yes                                                                              192 (19.6)              787 (80.4)   979      2.96[a](#prp2302-note-1009){ref-type="fn"}   2.23   3.93
  No                                                                               76 (7.6)                923 (92.4)   999      1                                                   
  Total                                                                            268                     1710         1978                                                         
  *χ* ^2^ = 60.829; *df* = 1; *P* \< 0.001[a](#prp2302-note-1009){ref-type="fn"}                                                                                                     

Statistically significant.
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Potential risk factors analysis {#prp2302-sec-0007}
-------------------------------

We subjected our finding to multinomial logistic regressions for potential risk factors and the presence of comorbidity and causation of ADR. The presence of comorbidity was found to be statistically significant with causation of AEs, *P *\< 0.0001 (CI: 1.98--3.96), In relating to specific types of comorbidity and the risk of developing an adverse events, HIV/AIDS and osteoarthritis were significantly (*P *\< 0.00) more associated with development of adverse events in this cohorts. Also age, weight and height of patients appears to be associated risk for adverse events *P *\<* *0.0001 (CI: 1.02--1.04), *P* \< 0.001 (CI: 1.017--1.03), and *P* \< 0.001 (CI: 1.007--1.02), respectively Table [6](#prp2302-tbl-0006){ref-type="table-wrap"}.

###### 

Simple and multiple logistic regression (multivariable analysis) of occurrence of adverse drug reaction (adr) on the associated factors

  Variable                          Simple logistic regression                    *P* ‐value   Multiple logistic regression   *P* ‐value                                                                                                    
  --------------------------------- --------------------------------------------- ------------ ------------------------------ ----------------------------------------------- -------------------------------------------- ------- -------- -----------------------------------------------
  Comorbidity (Yes/No)              2.80[a](#prp2302-note-1109){ref-type="fn"}    1.98         3.96                           \<0.001[a](#prp2302-note-1109){ref-type="fn"}   2.32[a](#prp2302-note-1109){ref-type="fn"}   1.48    3.65     \<0.001[a](#prp2302-note-1109){ref-type="fn"}
  Age (year)                        1.03[a](#prp2302-note-1109){ref-type="fn"}    1.02         1.04                           \<0.001[a](#prp2302-note-1109){ref-type="fn"}   1.01                                         0.99    1.02     0.581
  Sex (Female/Male)                 1.19                                          0.84         1.68                           0.322                                                                                                         
  Weight (kg)                       1.024[a](#prp2302-note-1109){ref-type="fn"}   1.017        1.03                           \<0.001[a](#prp2302-note-1109){ref-type="fn"}   1.01                                         0.99    1.02     0.394
  Height (cm)                       1.014[a](#prp2302-note-1109){ref-type="fn"}   1.007        1.02                           \<0.001[a](#prp2302-note-1109){ref-type="fn"}   1.01                                         0.992   1.02     0.288
  Traditional Medication (Yes/No)   0.35[a](#prp2302-note-1109){ref-type="fn"}    0.23         0.52                           \<0.001[a](#prp2302-note-1109){ref-type="fn"}   0.35[a](#prp2302-note-1109){ref-type="fn"}   0.21    0.57     \<0.001[a](#prp2302-note-1109){ref-type="fn"}
  Types of Antimalarial received                                                                                                                                                                                                            
  Artemether--Amodiaquine           0.854                                         0.1.453      3.798                          \<0.001[a](#prp2302-note-1109){ref-type="fn"}   0.245                                        0.638   1.014    \<0.001[a](#prp2302-note-1109){ref-type="fn"}
  Artemether--Lumefantrine          --                                            --           --                             --                                              --                                           --      --       --
  Pregnancy (Yes/No)                                                              0.144        18.562                         0.691                                           0.493                                        1.085   67.901   0.042

Statistically significant.
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Discussion {#prp2302-sec-0008}
==========

Artemisinin‐based combination therapy (ACT) as "antimalarial drugs, is the simultaneous use of two or more blood schizontocidal drugs with independent modes of action and thus unrelated biochemical targets in the parasite" ( Rashidul et al. [2007](#prp2302-bib-0036){ref-type="ref"}). ACTs as a chemotherapeutic agents can accelerate therapeutic response, improve cure rates and protect the component drugs against resistance (Field et al. [2001](#prp2302-bib-0013){ref-type="ref"}). However, the widespread nature of malaria infections all over the sub‐Saharan African countries especially Nigeria has led to a situation where it is common for malaria patients to have concurrent co‐infection with other disease such that when one is treating malaria, there is background comorbid conditions requiring additional therapy. This scenario has led to administration of polypharmacy to address multiple diseases which in turn make malaria patients more vulnerable to ADRs as is often the case with patients who has presence of many diseases and the use of many drugs.

Patients with co‐morbidity were found to be three times more likely to have these adverse drug reaction in our studies than those without co‐morbidity and it could be as low as two times and as high as four times (Odds ration = 2.96; 95% CI: 2.23--3.93). Also age, weight, and height of patients appears to be associated risk for adverse events *P* \< 0.0001 (CI: 1.02--1.04), *P* \< 0.001 (CI: 1.017--1.03), and *P* \< 0.001 (CI: 1.007--1.02). This is not surprising as risk factors reported to be independently associated with repeat admission due to ADRs included comorbidity, sex, multiple drug regimens and inappropriate use of medication, alcohol intake, poor cognitive function, and depression. (Carbonin et al. [1991](#prp2302-bib-0006){ref-type="ref"}; Field et al. [2001](#prp2302-bib-0013){ref-type="ref"}; Onder et al. [2002](#prp2302-bib-0033){ref-type="ref"}, [2003](#prp2302-bib-0034){ref-type="ref"}; Fialová et al. [2005](#prp2302-bib-0012){ref-type="ref"}; Klarin et al. [2005](#prp2302-bib-0024){ref-type="ref"}; Lima and Melo [2012](#prp2302-bib-0026){ref-type="ref"}). Although more patients had hypertension, peptic ulcer disease and diabetes, co‐morbidity with HIV/AIDS and osteoarthritis were the conditions that were statistically significant associated with development of ADR in our study. HIV increases the risk of malaria infection and clinical malaria in adults, especially in those with advanced immunosuppression (Whitworth et al. [2000](#prp2302-bib-0039){ref-type="ref"}; French et al. [2001](#prp2302-bib-0016){ref-type="ref"}; Ned et al. [2005](#prp2302-bib-0032){ref-type="ref"}; Chalwe et al. [2009](#prp2302-bib-0007){ref-type="ref"} ). In our study, the most common ADR recorded were weakness, dizziness, headache, vomiting, nausea, fever, abdominal pain, and insomnia which are in keeping with previous studies. (Linda et al. [2011](#prp2302-bib-0027){ref-type="ref"}; Bassi et al. [2012](#prp2302-bib-0002){ref-type="ref"}; Dodoo et al. [2014](#prp2302-bib-0010){ref-type="ref"}; WHO [2015](#prp2302-bib-0040){ref-type="ref"}). These symptoms were generally worse from the second and third day of treatment, but generally by the fifth day of drug administrations. In the settings with unstable malaria transmission, HIV‐infected adults are found to be at increased risk of complicated and severe malaria and (Table [7](#prp2302-tbl-0007){ref-type="table-wrap"}) death (Whitworth et al.[2000](#prp2302-bib-0039){ref-type="ref"}; French et al. [2001](#prp2302-bib-0016){ref-type="ref"}; WHO [2015](#prp2302-bib-0040){ref-type="ref"}). Reports also suggest that antimalarial treatment failure may be more common in HIV‐infected adults with low CD4‐cell counts compared to those not infected with HIV (Whitworth et al.[2000](#prp2302-bib-0039){ref-type="ref"}; French et al. [2001](#prp2302-bib-0016){ref-type="ref"}; Ned et al. [2005](#prp2302-bib-0032){ref-type="ref"}; Chalwe et al. [2009](#prp2302-bib-0007){ref-type="ref"}). The same pattern may apply to HIV and ADR due to ACT adverse drug reactions. Additional research is needed to investigate the impact of malaria on the natural history of HIV, potential therapeutic implications, and interactions at a cellular and molecular level. Furthermore, when AA was prescribed to HIV/AIDs patients on some anti‐retroviral drugs, ADRs were found to have increased (German et al. [2007](#prp2302-bib-0017){ref-type="ref"}). For example Efervirenz (EFV) is a potent inhibitor of CYP2C8 enzyme in vitro and may, therefore, potentially increase the plasma levels of amodiaquine when coadministered (German et al. [2007](#prp2302-bib-0017){ref-type="ref"}). However, the interaction is not expected to affect the therapeutic efficacy of the antimalarial, as both amodiaquine and its metabolite, N‐desethylamodiaquine, are active antimalarials, but it may have implications for toxicity. German et al. ([2007](#prp2302-bib-0017){ref-type="ref"}) and Churchill et al. ([1985](#prp2302-bib-0009){ref-type="ref"}) reported a case of 1.5--3fold increase in the area under the plasma concentration curve for amodiaquine when coadministered with EFV and artesunate to two HIV‐infected patients. The interaction between the drugs also resulted in asymptomatic but significant elevations in hepatic transaminases. Uriel and Lewthwaite ([2011](#prp2302-bib-0038){ref-type="ref"}) also reported a case of an HIV‐infected patient on abacavir (ABC), lamivudine (3TC), and NVP who also had *Plasmodium falciparum* malaria. More studies are therefore needed to explore the effects of AA coo administration in these medicines and as they are key first line drugs in HIV management in Nigeria.

###### 

Association between type of comorbidity and adverse drug reaction (ADR)

  Type of comorbidity              Adverse drug reaction   *χ* ^2^      *P*‐value            
  -------------------------------- ----------------------- ------------ ----------- -------- ---------------------------------------------
  Hypertension                     81 (42.2)               271 (77.0)   352         4.093    0.045
  Peptic ulcer disease             28 (17.4)               133 (82.6)   161         0.603    0.438
  Human immunodeficiency virus     8 (7.8)                 94 (92.2)    102         10.003   0.002[a](#prp2302-note-2009){ref-type="fn"}
  Diabetes mellitus                6 (14.0)                37 (86.0)    43          0.913    0.339
  Asthma                           6 (14.3)                36 (85.7)    42          0.790    0.374
  Osteoarthritis                   13 (43.3)               17 (56.7)    30          11.046   0.001[a](#prp2302-note-2009){ref-type="fn"}
  Sickle cell disease              3 (10.3)                26 (89.7)    29          1.628    0.202
  Hypertension/diabetes mellitus   5 (22.7)                17 (77.3)    22          0.139    0.710
  Pregnancy                        4 (28.6)                10 (71.4)    14          0.723    0.395
  Low back pain                    2 (15.4)                11 (84.6)    13          0.149    0.699
  Pelvic inflammatory disease      1 (8.3)                 11 (91.7)    12          0.980    0.322
  Tuberculosis                     3 (25.0)                9 (75.0)     12          0.224    0.636
  Difficulty in seeing             5 (41.7)                7 (58.3)     12          3.748    0.053
  Injury                           3 (27.3)                8 (72.7)     11          0.414    0.520
  Insomnia                         0 (0)                   9 (100)      9           2.216    0.137
  Seizures                         1 (11.1)                8 (88.9)     9           0.416    0.519
  Surgery                          2 (22.2)                7 (77.8)     9           0.039    0.843
  Others                           21 (21.6)               76 (78.4)    97          0.284    0.594

Statistically significant.
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Osteoarthritis has been consistently associated with factors that predict ADRs. Recently, Zhang et al. [2009](#prp2302-bib-0041){ref-type="ref"} observed in a retrospective cohort study of comorbidity and repeat admission to hospital for adverse drug reactions in older adults, that Compared with patients who had no recorded comorbidity, the analysis identified sizeable adjusted hazard ratios that comorbidity with rheumatological disease, congestive cardiac failure, peripheral vascular, chronic pulmonary, hepatic, renal and malignant diseases predict readmission for ADRs (Zhang et al. [2009](#prp2302-bib-0041){ref-type="ref"}).

Regardless of symptoms, the presence of plasmodial parasites in a pregnant woman\'s body will have a negative impact on her own health and that or her fetus. Malaria in pregnancy is different from the disease in the non‐pregnant state. The increased severity of malaria in pregnancy is thought to be due to general impaired immunity plus a diminution of acquired immunity to malaria in endemic areas. Placental malaria occurs where *Plasmodium falciparum*‐infected erythrocytes accumulate in the intervillous space of the placenta but may be rare or absent in the peripheral circulation (Chalwe et al. [2009](#prp2302-bib-0007){ref-type="ref"}; Bassi et al. [2012](#prp2302-bib-0002){ref-type="ref"}; Dodoo et al. [2014](#prp2302-bib-0010){ref-type="ref"}). One would expect pregnancy to be significantly associated with ADR going by previous findings by Bassi et al. [2012](#prp2302-bib-0002){ref-type="ref"}; but this was not the case in this study. This is probably because of the insufficient number of pregnant patients 14 (1.4%) seen in the cohort. Preventing and treating malaria in pregnancy can be a key intervention to improving maternal, fetal and child health globally and are linked to three of the Millennium Development Goals (UN. Report [2015](#prp2302-bib-0037){ref-type="ref"}).

Taking AA is significantly associated with ADR in our studies. This is in keeping with findings in literature (McGready et al. [2001](#prp2302-bib-0029){ref-type="ref"}; Bassi et al. [2012](#prp2302-bib-0002){ref-type="ref"}; Chatio et al. [2016](#prp2302-bib-0008){ref-type="ref"}). Though no pharmacokinetic interactions have been documented, amodiaquine and desethylamodiaquine inhibit CYP 2D6 in vitro and may cause clinically significant interactions with some *β*‐blockers, antidepressants, and antipsychotics drugs. The presence of many patients with hypertension might have allow drug--drug interactions. It therefore underscore the importance of cautions while treating patients with malaria and comorbid conditions to pay special attention to drug--drug interactions and pharmacovigilance.

Conclusions {#prp2302-sec-0009}
===========

Patients with co‐morbidity were three times more likely to have adverse drug reaction in our studies than those without co‐morbidity and it could be as low as two times and as high as four times. Although more patients had hypertension, peptic ulcer disease and diabetes, co‐morbidity with HIV/AIDS and osteoarthritis were the conditions that were statistically significant in causing ADR in our study. It is therefore recommended that clinicians should ensure close monitoring of patients with comorbid conditions to optimize therapy and prevent or minimized AEs as we call for more studies in these areas.
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